Back to top

Bull of the Day

Osiris Therapeutics (OSIR) reported third quarter earnings of $0.14 per share, well above the Zacks Consensus Estimate of a profit of $0.04 and the year-ago loss of $0.21. Results were mainly driven by lower operating expenses. Revenues of $10.8 million were just above the Zacks Consensus Estimate of $10 million.

Lead pipeline candidate Prochymal has the potential to be a sort of a wonder drug for various inflammatory or tissue damage indications. Prochymal could be a billion-dollar blockbuster product if all development goes well. Meanwhile, the sales opportunity for Chondrogen, the company's second pipeline candidate, could also be significant.

We view the company's collaboration agreement with large-cap biotech Genzyme as a positive. We believe the current share price represents an attractive entry point and maintain our Outperform rating on the stock. Based on third quarter results, we have increased our 2010 and 2011 earnings estimates.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
PLANAR SYST… PLNR 4.44 +5.21%
BITAUTO HOL… BITA 81.71 +5.12%
CTPARTNERS… CTP 16.66 +4.26%
CHINA BIOLO… CBPO 47.91 +3.30%
MALLINCKROD… MNK 72.94 +2.85%